BridgeBio Oncology Therapeutics, Inc.(BBOT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.14
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BBOT

11/13/2026: BBOT (1-star) is currently NOT-A-BUY. Pass it for now.

BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company developing precision small-molecule therapies for RAS-driven and PI3Kα-driven cancers. Its core strengths lie in a wholly owned pipeline featuring differentiated candidates like BBO-8520 and BBO-11818 designed to tackle drug resistance. The primary investment story centers on upcoming clinical data readouts and strategic combination trials that could validate its targeted oncology approach. However, the company faces substantial risks, including zero commercial revenues, high clinical attrition rates, and intense competition from well-funded peers. This stock suits growth-oriented investors with a high risk tolerance who are comfortable with binary clinical milestones and capital volatility.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers high-growth potential driven by novel oncology pipeline readouts, tempered by early-stage clinical risks.
Momentum investorStrong fit while signal remains positiveStock price can experience sharp momentum shifts around major clinical data catalysts and trial updates.
Value investorWeak fitLacks commercial revenue, earnings, or traditional valuation metrics.
Dividend investorWeak fitThe company pays no dividends and reinvests all capital into clinical programs.
Low-risk investorWeak fitHigh binary clinical trial risk and share price volatility make it unsuitable for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks frequently experience dramatic price swings based on trial outcomes and market conditions.
Valuation riskHighValuation is entirely speculative based on future pipeline potential rather than current cash flows or earnings.
Competition risk (KRAS and precision oncology competitors)Medium / highCompeting firms developing alternative targeted therapies could outpace or outperform BBOT's pipeline assets.
Business qualityMediumThe company features specialized scientific talent and promising intellectual property, but lacks a commercial commercialized franchise.
Dividend incomeLow / noneNo dividend is paid or expected in the near term.
Execution riskHighSuccess depends entirely on clinical trial execution, regulatory clearance, and effective management of capital resources.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 171.74M USD
Price to earnings Ratio 4.04
1Y Target Price 21
Price to earnings Ratio 4.04
1Y Target Price 21
Volume (30-day avg) 630.4K shares
Beta 0.85
52 Weeks Range 1.98 - 14.87
Updated Date 11/15/2026
52 Weeks Range 1.98 - 14.87
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.53

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -38.2%
Avg. Invested days 25
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BBOT receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
BBOT has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-80.5%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
BBOT's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
BBOT's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-80.5%, negative) and free-cash-flow growth (-14890.4%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 76.6% and approximately 44.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 27.14% supports management-shareholder alignment.

Top 5 Institutional Investors

Cormorant Asset Management, LLC 22.28%
Deerfield Management Co 6.09%
Omega Fund Management LLC 4.10%
Alphabet Inc 3.52%
EcoR1 Capital, LLC 3.52%

Unit Economics (Per $1K Revenue)

★★★★★
BBOT generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
BBOT has a Value-Oriented profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedSmall / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Therapeutics DevelopmentFuture commercialization or out-licensing of small-molecule oncology drugs targeting RAS and PI3Kα pathways.The company currently generates zero revenue and relies on future drug approvals or partnerships to commercialize its pipeline.

Valuation

Trailing PE 4.04
Forward PE -
Enterprise Value -20.55M
Price to Sales(TTM) -
Enterprise Value -20.55M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 80.25M
Shares Floating 35.85M
Shares Outstanding 80.25M
Shares Floating 35.85M
Percent Insiders 27.14
Percent Institutions 76.62

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.